This article was accepted for publication after full peer-review.
Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis
Article first published online: 23 MAR 2014
© 2014 John Wiley & Sons Ltd
Alimentary Pharmacology & Therapeutics
Volume 39, Issue 10, pages 1213–1224, May 2014
How to Cite
Saxena, V., Manos, M. M., Yee, H. S., Catalli, L., Wayne, E., Murphy, R. C., Shvachko, V. A., Pauly, M. P., Chua, J., Monto, A. and Terrault, N. A. (2014), Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis. Alimentary Pharmacology & Therapeutics, 39: 1213–1224. doi: 10.1111/apt.12718
- Issue published online: 16 APR 2014
- Article first published online: 23 MAR 2014
- Manuscript Accepted: 1 MAR 2014
- Manuscript Revised: 25 FEB 2014
- Manuscript Revised: 16 FEB 2014
- Manuscript Received: 24 JAN 2014
- NIH. Grant Number: T32 DK060414
- VA Merit Funding. Grant Number: 1I01 CX000295-01A1
- Liver Center. Grant Number: NIH P30 DK 026743
|apt12718-sup-0001-FigureS1.tif||image/tif||16236K||Figure S1. Receiver operator curves for prediction of baseline bilirubin on achievement of non-SVR12 (Panel A), of baseline INR on achievement of non-SVR12 (Panel B), of baseline albumin on achievement of SVR12 (Panel C) and of baseline platelets on achievement of non-SVR12.|
Table S1. Univariate predictors of SVR12 in HCV genotype 1 patients with cirrhosis undergoing PI triple therapy.
Table S2. Adverse events leading to early discontinuation of PI triple therapy.
Table S3. Univariate predictors of early treatment discontinuation due to adverse event(s).
Table S4. Univariate predictors of SVR12 in HCV genotype 1 patients with mildly decompensated cirrhosis (Child-Pugh ≥6) undergoing PI triple therapy.
Table S5. Univariate predictors of early treatment discontinuation due to adverse event(s) among patients with mildly decompensated cirrhosis (Child Pugh ≥6).
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.